Mod 6 part 1 quiz Flashcards

1
Q

what is heart failure

A

progressive disorder r/t ventricular dysfunction, reduced CO, volume overload, and insufficient tissue perfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Symptoms of HF

A

fatigue
weakness
sob, orthopnea, PND
early satiety
increased JVP
edema
ascites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Natriuretic peptides

A

ANP and BNP hormones released in response to stretch of atria and dilation of ventricles
-promote arteriole and veins dilation
-promote loss of Na and water by kidneys
-helps balance vasoconstriction by SNS and angiotensin II caused by RAAS, but eventually becomes overwhelmed as CHF progresses
-BNP are key indicators for CHF status
lower BNP=better outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HF treatment

A

-focus on increasing forward flow and decreasing backup of flow
-decreasing afterload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What medications increase forward flow by increase force of contractions

A

Inotropes- digoxin, milrinone, dobutamine
Beta blockers: decrease rate allowing increase filling time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Decrease backward flow/preload

A

vasodilators/nitrates-slow return from veins to heart
diuretics to decrease intravascular volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Decrease afterload

A

-ace inhibitors and hydralazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Prototype diuretics

A

Loop diuretics: furosemide (most effective)
Thiazide diuretics: E.g. Hydrochlorothiazide (moderate diuresis)-only used with minimal edema
Potassium sparing diuretics: Spironolactone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Furosemide (indications, MOA)

A

Indications: Pulmonary edema, CHF, hepatic congestion, resistant HTN that does not respond to other diuretics
MOA: acts in loop of Henle to block reabsorption of Na and Cl to prevent passive reabsorption of water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diuretic complications

A

Severe dehydration or hypovolemia: may present as excessive weight loss, dry mouth, tenting skin, increase thirst
-acid base imbalance
-hypotension
-renal impairement
-electrolyte abnormlaities (hypokalemia)
-ototoxicity (increased risk with use of aminoglycoside)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Potassium sparing diuretics

A

-moderately increase urine production and decrease K excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

2 subcategories of Potassium sparing diuretics

A

aldosterone antagonist: spironolactone
non-aldosterone antagonist: triamterene and amiloride

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

spironolactone
MOA,inications, complication

A

blocks action of aldosterone in the distal nephron, causes retention of K and increased excretion of Na
indication: blood pressure management, edema (not indicated for monotherapy), and CHF
Major complication: Hyperkalemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Agents affecting volume and ion contents

A

Na and Chloride are influenced by diuretics
-loop and thiazides may cause hypokalemia, hypomangensmia
potassium sparing diuretics-helpful for hypokalemia
Monitor: BMP, Mg, phos closely w/ diuretic use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Prototype drugs acting on RAAS

A

ACEI: lisinopril
ARB:losartan
DRI: aliskiren
Aldosterone antagonist: eplernone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drugs acting on RAAS

A

activated by low perfusion from the heart that causes release of renin
-arterial BP decreases causes decrease GFR
-effects results in vasoconstriction and renal retention of Na and water–>elevates BP
-ACEI blocks conversion of angiotensin I to angiotensin II
-ARBS block angiotensin II receptor to prevent effects
-both medications result in less vasoconstrictive effects–> lower bp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ACEI

A

angiotensin II regulates arterial bp through vasoconstriction and stimulation of aldosterone release
-MOA: 1. reduces angiotensin II levels–>dilate blood vessels, reduce blood volume, prevent pathological changes to the heart and blood vessels
2. increases level of bradykinin–> vasodilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ACEI indications

A

-essential HTN
-HF-part of GDMT for SHF (EF<40%)
-MI
diabetic and nondiabetic nephropathy-renoprotective, can help slow progression of renal disease

19
Q

ACEI adverse effects

A

-First dose hypotension-precipitous drop in BP after first dose
-increase levels of bradykinin may result in cough and/or angioedema
-hyperkalemia
-neutropenia
-renal failure-espeically in those with bilateral renal artery stenosis
-Do not use in 2nd or 3rd trimester of pregnancy

20
Q

ARBs

A

indications: similiar to those of ACEIs (CHF, HTN, Post MI, stroke prevention, diabetic nephropathy/retinopathy)
MOA:blocking actions of Angiotensin II
1. dilate arteries and veins–>prevent pathologic changes in cardiac structure
2. decrease aldosterone release
-generally used when ACEIs are intolerable
Adverse effects: renal failure (especially in those with bilateral renal artery stenosis)
-compared to ACEIs less likely to develop hyperkalemia and/or angioedema

21
Q

Used in place of an ACEI/ARB

A

Entresto (ARNI) angiotensin receptor neprilysin inhibitor
-newer med for stage II-IV HF
-found to be superior to enalapril
Adverse effects: angioedema, hyperkalemia, hypotension

22
Q

Vasodilators

A

differ based on blood vessels they effect
hydralazine and manoxidile-cause selective dilation of arterioles
nitroprusside: cause dilation of arteriols and veins

23
Q

Hydralazine

A

indications: Essential HTN and CHF (isosorbide dinitrate can reduce afterload)
-MOA: dilation of arterioles (little to no effect on veins)
Adverse effects: reflex tachycardia, increased blood volume, systemic lupus erythematosus-like syndrome
Low risk for postural hypotension, but when used with additional anti-hypertensive initiate at low doses

24
Q

Inotropes

A

Oral: Digoxin
IV: sympathomimetic: dopamine and dobutamine
phosphodiesterase: milrinone

25
Q

Digoxin

A

-cardiac glycoside
-indications: positive inotrope, second line CHF
-increased myocardial contractile force, increase CO, neurohormonal benefits
MOA: inhibits enzyme sodium-potassium adenosine triphosphatase–>calcium accumulation within myocytes causing contractile force
Adverse effect: dysrhythmias, anorhexia, N,V, fatigue, visual disturbances (yellow tinge, halos around dark objects)
Goal range .5-.8 ng/ml

26
Q

Inotrope given for decompensated heart failure for short term therapy

A

phosphodiesterase inhibitirs: IV milrinone

27
Q

milrinone

A

-used for severe decrease cardiac output and decrease organ perfusion
moa: increases myocardial contractility and promotes vasodilation
adverse effect: induce dysrhythmias, myocardial ischemia from increased metabolic demand

28
Q

no identifiable cause, chronic and progressive

A

primary HTN

29
Q

primary htn

A

Atreatment: lifestyle modifications–>exercise, dietary changes, weight loss, low Na diet
pharm treatment:
diuretics: decrease blood volume
vasodilators: decrease arterial resistance
CCB: block ca activated smooth muscle contraction
Aldosterone antagonist: block aldosterone
ACE/ARB: block RAAS

30
Q

elevated BP d/t an identifiable primary cause

A

secondary HTN

31
Q

secondary hypertension

A

common secondary causes relate to procceses that increase arterial resistance, blood volume, and/or co

32
Q

common causes of secondary HTN

A

renal artery stenosis, cushings, hyperaldosteronism, hyperthyroidism, vasculitis, increase epi/norepi r/t pheochromocytoma

33
Q

HTN guideline care

A

-refer to journal of american college of cardiology guidelines
-1st rec lifestyle modification
-if no improvement start single drug
-if inadequate response or poorly tolerated, then, add or transition to second agent
-assess reason for failure prior to making changes
-drugs must come from diff classes
-using 2 different drugs allows bp effects through diff mechanisms, allow for lower doses–>less risk for side effects, agents can offset adverse effects of the other

34
Q

CCB

A

verapamil-nondihydropyridine- affects heart and blood vessles
nifedipine-dyhydropyridine, affects blood vessels

35
Q

Verapamil indications

A

angina pectoris, essential HTN, cardiac dysrhymthimas

36
Q

Verapamil MOA

A

MOA: block Ca channels in blood vessels and heart
Blockade at: 1. peripheral arterioles causing dilation and decrease arterial pressure 2. arteries and arterioles of heart to cause increase coronary perfusion 3. SA node reducing HR 4. AV node decreasing AV nodual conduction 5. Myocardium causes decreased force of contraction

37
Q

Verapamil adverse effects

A

Adverse Effects: constipation, dizziness, facial flushing, headache, and ankle/feet edema

38
Q

Diltiazem indications

A

CCB
Indications: same as verapamil (angina pectoris, essential HTN, cardiac dysrhythmias)

39
Q

Diltizem MOA

A

blocks Ca channel blockers in the heart and blood vessels

40
Q

Diltiazem adverse effects

A

less constipation than verapamil, dizziness, facial flushing, headache, ankle/feet edema
-exacerbate cardiac dysfunction with bradycardia, SSS, CHF, and heart blocks

41
Q

What med causes chronic examoatous rash in the elderly

A

Diltiazem

42
Q

How to improve non-adherence

A

-Patient education
-minimize side effects
-establish collaborative relationship
-simplify regimen by minimizing frequency and utilizing combo drugs
-cost effective regimen
-involve family
-schedule appointments at convenient times for patients

43
Q

-Optimal diuretic for patients with renal impairment or decreased GFR
-Able to promote diuresis even with low renal blood flow

A

Loop diuretics- E.g. Furosemide, Torsemide, Bumetanide, Etha crynic

44
Q

First line CHF

A

-beta blockers